Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000;49 Suppl 1(Suppl 1):15S-20S.
doi: 10.1046/j.1365-2125.2000.00148.x.

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

K D Wilner  1 , T G Tensfeldt, B Baris, T A Smolarek, R Z Turncliff, W A Colburn, R A Hansen
Affiliations
Clinical Trial

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

K D Wilner et al. Br J Clin Pharmacol. 2000.

Abstract

Aims: To compare the pharmacokinetics of ziprasidone in healthy young (18-45 years) men and women, and healthy elderly (> or = 65 years) men and women.

Methods: Eight young men, 11 young women, 8 elderly men and 8 elderly women were given oral ziprasidone 40 mg day(-1), in two evenly divided daily doses, for 7 days, followed by a single 20 mg dose on day 8. Serum samples were collected immediately before the morning dose on days 1-8, for up to 12 h after dosing on day 1 and for up to 96 h after dosing on day 8. The resulting data were used to derive pharmacokinetic parameters of ziprasidone in each age and gender group.

Results: Steady-state serum concentrations of ziprasidone were achieved within 2-3 days. The steady-state pharmacokinetics of ziprasidone, determined 8 days after the initiation of treatment, were similar in the young men, elderly men and young women. Assessment of gender effects by analysis of variance revealed statistically significant differences in Cmax (85 vs. 69 ng ml(-1) and tmax (3.19 vs. 4.81 h) but no differences in AUC(0,12 h) or lambda(z). Assessment of age effects by analysis of variance revealed statistically significant differences in AUC(0,12 h) (560 vs. 465 ng ml(-1) h), Cmax (85 vs. 69 ng ml(-1) and lambda(z) (0.126 vs. 0.197 l h(-1) but no difference in tmax. Assessment of age and gender effects by analysis of covariance, with body weight as the covariate, did not reveal any significant differences. The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively. Standard deviations of the means for the pharmacokinetic parameters for the elderly women tended to be large.

Conclusions: The influence of age and gender on the pharmacokinetics of ziprasidone is not clinically significant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean ziprasidone serum concentrations following administration of a single ziprasidone 20 mg dose to healthy young men (–––), young women (-·-·), elderly men (----) and elderly women (…..).
Figure 2
Figure 2
Mean ziprasidone serum concentrations on day 8 following administration of ziprasidone 20 mg twice daily for 8 days to healthy young men (–––), young women (-·-·), elderly men (----) and elderly women (…..).
Figure 3
Figure 3
Individual AUC(0,12 h) following administration of ziprasidone 20 mg twice daily for 8 days to healthy young men (♦), young women (◊), elderly men (▪) and elderly women (□). Group means are denoted by horizontal lines.
Figure 4
Figure 4
Individual Cmax following administration of ziprasidone 20 mg twice daily for 8 days to healthy young men (♦), young women (◊), elderly men (▪) and elderly women (□). Group means are denoted by horizontal lines.
See this image and copyright information in PMC

References

    1. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(Suppl. 1):5S–13S. - PMC - PubMed
    1. Howard HR, Lowe JA, Seeger TF, et al. 3 – Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996;39:143–148. - PubMed
    1. Metropolitan height and weight tables Stat Bull Metrop Life Found. 1983;64:3–9. - PubMed
    1. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatogr. 1995;668:133–139. - PubMed
    1. Snoeck E, Van Peer A, Sack M. Influence of age, renal and liver impairment on the pharmacokinetics or risperidone. Psychopharmacology. 1995;122:223–229. - PubMed

Publication types